TNF阻滞剂在类风湿关节炎临床试验中的疗效因对照药不同而异:lessebo效应的荟萃分析
该荟萃分析比较了TNF阻滞剂参考药在安慰剂对照优效试验与生物类似药活性对照等效试验中的疗效。纳入31项试验,参考药在生物类似药对照组的ACR20应答率70%显著高于安慰剂对照组的59%,ACR50应答率44%对35%也有显著差异。提示活性对照试验中可能存在安慰剂效应增强或安慰剂对照试验中反安慰剂效应,称为lessebo效应。
要点
- TNF阻滞剂参考药在生物类似药对照试验中的ACR20应答率70%高于安慰剂对照试验的59%。
- ACR50应答率在生物类似药对照试验中为44%,也显著高于安慰剂对照试验的35%。
- 两组人群特征相似,疗效差异可能与安慰剂效应或反安慰剂效应有关。
核心结论
- TNF阻滞剂参考药在与活性药物对照时的疗效优于与安慰剂对照时的疗效,可能反映活性对照试验中安慰剂效应增强或安慰剂对照试验中反安慰剂效应,称为lessebo效应。
研究设计与样本
- 检索PubMed、EMBASE和Cochrane数据库截至2020年3月的随机双盲对照试验,比较生物参考药与安慰剂或生物类似药。
- 共纳入31项试验,评估参考药在安慰剂对照组和生物类似药对照组的ACR20/50/70应答,采用随机效应模型合并并用荟萃回归比较。
主要发现
- 参考药在生物类似药对照组的ACR20应答率为70%(95%CI 66-74),高于安慰剂对照组的59%(95%CI 55-62),P=0.001。
- 参考药在生物类似药对照组的ACR50应答率为44%(95%CI 39-50),高于安慰剂对照组的35%(95%CI 31-39),P<0.01。
- 两组人群的病程、疾病活动度、血清阳性率和甲氨蝶呤剂量等主要特征相似。
临床怎么用
- 解读TNF阻滞剂临床试验结果时需考虑对照药类型对疗效估计的影响,活性对照试验中的疗效可能被高估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effect of the biological reference agents (infliximab, etanercept, adalimumab) in RA in pivotal superiority placebo-controlled trials (reference agent vs placebo) vs their effect in equivalence active comparator-controlled trials (reference agent vs biosimilar). METHODS: The PubMed, EMBASE and Cochrane databases were searched for randomized, double-blind, controlled trials up to March 2020 comparing a biological reference agent vs placebo or biosimilar. The study assessed the ACR 20/50/70 responses of the reference agent in these groups (Reference-pbo and Reference-bs, respectively). The effect of the reference agent in both groups was estimated with 95% CI, pooled using random-effects models and then compared using a meta-regression model. RESULTS: We included 31 trials. The main characteristics of the population (disease duration and activity, % seropositivity and methotrexate dose) of the population in both groups were similar. The meta-analysis found a better ACR20 response to the biological originator in the Reference-bs group with a global rate of 70% (95% CI, 66, 74) compared with 59% (95% CI, 55, 62) in the reference-pbo group (P =0.001). A significant difference was also found for ACR 50 [44% (95% CI, 39, 50) vs 35% (95% CI, 31, 39), respectively, P <0.01]. CONCLUSION: The effect of the reference biologic agent was better when compared with an active drug to a placebo. This could be linked to an increased placebo effect in active comparator-controlled studies or a nocebo effect in placebo-controlled studies. This effect can be called the lessebo effect.
引用
- Lopez L, Griffier R, Barnetche T, et al. The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis. Rheumatology (Oxford). 2022. PMID: 34382085. doi:10.1093/rheumatology/keab630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。